ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 1398 • 2019 ACR/ARP Annual Meeting

    Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)

    Christine Xu1, Patrick Nolain 2, Qiang Lu 3, Anne Paccaly 4, Melitza Iglesias-Rodriguez 5, Gregory St John 6, Chad Nivens 4, Rafael Maldonado 7, Tomonori Ishii 8, Ernest Choy 9 and Vanaja Kanamaluru 3, 1Sanofi, Bridgewater, NJ, 2Sanofi-Aventis, Montpellier, France, 3Sanofi, Bridgewater, 4Regeneron Pharmaceuticals, Inc., Tarrytown, 5Sanofi Genzyme, Cambridge, MA, 6Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 7Pompeu Fabra University, Barcelona, Spain, 8Tohoku University Hospital, Sendai, Japan, 9Cardiff University School of Medicine, Cardiff, United Kingdom

    Background/Purpose: The in vitro binding affinity of sarilumab (KD 61.9 pM) for the human interleukin-6 receptor (IL-6R) is 15–22-fold higher than that of tocilizumab. This…
  • Abstract Number: L18 • 2018 ACR/ARHP Annual Meeting

    A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab

    Gerd R. Burmester1, Frank Buttgereit1, Corrado Bernasconi2, Jose Maria Alvaro-Gracia3, Nidia Castro2, Maxime Dougados4, Cem Gabay5, Jacob van Laar6, J. Michael Nebesky2, Attila Pethö-Schramm2, Carlo Salvarani7, Marc Y. Donath8 and Markus R. John2, 1Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 2F. Hoffmann-La Roche, Basel, Switzerland, 3Hospital Universitario de La Princesa IIS-IP, Madrid, Spain, 4Université Paris-Descartes, Paris, France, 5University Hospitals of Geneva, Geneva, Switzerland, 6University Medical Centre Utrecht, Utrecht, Netherlands, 7Università de Modena e Reggio Emilia, Modena, Italy, 8University Hospital Basel, Basel, Switzerland

    Background/Purpose: Guidelines recommend low-dose, short-duration glucocorticoid (GC) treatment for RA,1,2  but long-term use, especially at prednisone-equivalent doses >5 mg/d, should be avoided.2 Many patients (pts)…
  • Abstract Number: 615 • 2018 ACR/ARHP Annual Meeting

    The Comparative Observational Study about Efficacy, Safety and Adherence between Tocilizumab and Infliximab in Patients with Rheumatoid Arthritis

    Mayumi Matsuda1, Yu Funakubo Asanuma2, Yoshinobu Nakao3, Hiroaki Yazawa2, Takuma Tsuzuki Wada4, Noritsune Kouzu5 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Department of Rheumatology, Saga University Hospital, Saga, Japan, 4Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, 5Saitama Medical University, Moroyama, Japan

    Background/Purpose: Since 2003 in Japan, biologic agents have become widely used for RA patients in whom csDMARDs were ineffective. Tocilizumab (TCZ) was approved for marketing…
  • Abstract Number: 958 • 2018 ACR/ARHP Annual Meeting

    Tocilizumab and the Risk for Cardiovascular Disease Events Among Rheumatoid Arthritis Patients: A Direct Comparison in Real World Setting

    Fenglong Xie1, Huifeng Yun1, Emily Levitan2, Paul M. Muntner2 and Jeffrey R. Curtis1, 1University of Alabama at Birmingham, Birmingham, AL, 2Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Multiple studies have observed unfavorable changes in lipid profile associated with tocilizumab (TCZ, anti-IL6 receptor antagonists) and some other rheumatoid arthritis (RA) therapies. The…
  • Abstract Number: 1174 • 2018 ACR/ARHP Annual Meeting

    Comparative Cost per Response for Four Clinical Outcomes of Tocilizumab Monotherapy Versus Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial in Patients with Rheumatoid Arthritis

    Jennie H. Best and Jinglan Pei, Genentech, Inc., South San Francisco, CA

    Background/Purpose: The cost-effectiveness of different biologic therapies is an important component in guiding treatment decisions for patients with rheumatoid arthritis (RA). The objective of this…
  • Abstract Number: 1514 • 2018 ACR/ARHP Annual Meeting

    Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis

    Dimitrios A. Pappas1, Carol J. Etzel2, Margaux Crabtree3, Jennie H. Best4, Steve Zlotnick4 and Joel Kremer5, 1Columbia University, New York, NY, 2Corrona LLC, Waltham, MA, 3Corrona, LLC, Waltham, MA, 4Genentech, Inc., South San Francisco, CA, 5Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: Few real-world studies have evaluated the impact of comorbidity burden or obesity on the effectiveness of tocilizumab (TCZ) for the improvement of rheumatoid arthritis…
  • Abstract Number: 1543 • 2018 ACR/ARHP Annual Meeting

    The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis

    Takuma Tsuzuki Wada1, Yu Funakubo Asanuma2, Mayumi Matsuda3, Hiroaki Yazawa2, Yoshinobu Nakao4, Noritsune Kozu5 and Toshihide Mimura2, 1Department of Rheumatology and Applied Immunology, Faculty of Medicine,, Saitama Medical University, Saitama, Japan, 2Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 3Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 4Department of Rheumatology, Saga University Hospital, Saga, Japan, 5Kozu Orthopedic Clinic, Yachiyo, Japan

    Background/Purpose: Elderly patients with rheumatoid arthritis (RA) have declined physical performances and increased various complications. We are concerned about decrease of efficacy and increase of…
  • Abstract Number: 570 • 2018 ACR/ARHP Annual Meeting

    Evaluation of CXCL13, sICAM1, MMP-3 and S100A8/A9 As Serum Biomarkers in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab

    D. James Haddon, Thierry Sornasse, Michael J. Townsend, Jinglan Pei and Margaret Michalska, Genentech, Inc., South San Francisco, CA

    Background/Purpose: Serum levels of C-X-C motif chemokine ligand 13 (CXCL13) and soluble intercellular adhesion molecule-1 (sICAM-1) have been associated with outcomes in patients with rheumatoid…
  • Abstract Number: 572 • 2018 ACR/ARHP Annual Meeting

    Combining Tocilizumab with Methotrexate Improves Sustainability. Real World Evidence Report from Quebec Database Rhumadata®

    Denis Choquette1, Louis Bessette2, Jacques Brown2, Boulos Haraoui1, Frédéric Massicotte1, Jean-Pierre Pelletier1, Jean-Pierre Raynauld1, Marie-Anaïs Rémillard1, Diane Sauvageau1, Angèle Turcotte2, Édith Villeneuve1 and Louis Coupal1, 1Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, 2Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada

    Background/Purpose: Biologic therapy targeting TNF have consistently demonstrated better efficacy and effectiveness when combined with a conventional synthetic DMARD (csDMARD), most frequently methotrexate. Although pre-clinical…
  • Abstract Number: 573 • 2018 ACR/ARHP Annual Meeting

    Subcutaneous Tocilizumab in Monotherapy or in Combination with DMARD in Patients with Moderate to Severe Active Rheumatoid Arthritis: Observational Study to Describe Real-World Drug Retention Rate at 12 Months, Interim Analysis

    Pascal Hilliquin1, Thomas Barnetche2, Guy Baudens3, Ralph Niarra4, Isabelle Idier5 and Alain Saraux6, 1Rheumatology, Hôpital Sud Francilien, Corbeil-Essonne, France, 2Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, 3Rheumatology, CHR Valenciennes, Valenciennes, France, 4Biostatistics, Keyrus of behalf of Roche SAS, Boulogne-Billancourt, France, 5Medical department, Chugai Pharma France, Paris La Defense, France, 6Rheumatology, CHU Brest, Brest, France

    Background/Purpose: In France, tocilizumab (TCZ) subcutaneous (sc) 1st prescription and yearly renewal are restricted to hospital. Monitoring may be done by both office-based or hospital…
  • Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting

    Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE

    Anne C. Bay-Jensen1, Christian S. Thudium1, Claus Christiansen2 and Morten A. Karsdal1, 1Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Clinical Development, Herlev, Denmark

    Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
  • Abstract Number: 1467 • 2017 ACR/ARHP Annual Meeting

    Changes in the Immune Response of RA Patients Induced By 1 Year of Tocilizumab

    Cesar Diaz-Torné1, Paula Estrada2, Patricia Moya3, Maria A. Ortiz4, Diana de la Fuente5, Mireia Moreno6, Noemí Busquets7, Julio Ramírez8, Carme Moragues9, Sergi Ros5, Enrique Casado Burgos6, Vicente Torrente10, Elizabeth Garcia11, Manel Pujol12, Andrés Ponce13, Silvia Vidal4 and Juan José de Agustín14, 1Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, 2Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, Barcelona, Spain, 3Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 4Institut de Recerca Sant Pau, Barcelona, Spain, 5Rheumatology, Hospital de Viladecans, Viladecans, Spain, 6Rheumatology, Parc Tauli Hospital Universitari, Sabadell, Spain, 7Rheumatology, Hospital General de Granollers, Granollers, Spain, 8Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 9Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 10Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, L'Hospitalet de Llobregat, Spain, 11Rheumatology, Hospital de Mollet, Mollet, Spain, 12Hospital Mútua de Terrassa, Terrassa, Spain, 13Rheumatology. Internal Medicine, Hospital General de Granollers, Granollers, Spain, 14Rheumatology, Hospital Vall d´Hebrón, Barcelona, Spain

    Background/Purpose: Tocilizumab, a humanized anti-human IL-6 receptor antibody that blocks the signaling of IL-6/IL-6R complex, is an effective treatment in chronic inflammatory rheumatoid arthritis (RA).…
  • Abstract Number: 1476 • 2017 ACR/ARHP Annual Meeting

    Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial

    Xavier M Teitsma1, Johannes WG Jacobs1, Paco MJ Welsing2, Attila Pethö-Schramm3, Michelle EA Borm4, Jacob M. van Laar5, Floris PJ Lafeber5 and Johannes W.J. Bijlsma2, 1Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3F. Hoffmann-La Roche, Basel, Switzerland, 4Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, 5Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Patient-reported outcomes are, in addition to other efficacy and safety related outcomes, important reflections of effectiveness and adverse effects of a therapy. The Outcomes…
  • Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting

    Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis

    Michaela Koehm1, Michael Hofmann2, Rasmus Lüthje2, Matthew McIntosh3, Varghese Abraham3, Cem Gabay4, Arthur Kavanaugh5, Harald Burkhardt6 and Frank Behrens6, 1Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, 2Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, 3Genentech, San Francisco, CA, 4SCQM, Geneva, Switzerland, Geneva, Switzerland, 5Medicine, University of California, San Diego, La Jolla, CA, 6Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany

    Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…
  • Abstract Number: 1905 • 2017 ACR/ARHP Annual Meeting

    Sustained Response Following Discontinuation of Methotrexate in Patients with Rheumatoid Arthritis Treated with Subcutaneous Tocilizumab: Results from a Randomized Controlled Trial

    Joel Kremer1, William F C Rigby2, Nora Singer3, Christine Birchwood4, Darcy Gill4, William Reiss4, Jinglan Pei4 and Margaret Michalska4, 1Albany Medical College, Albany, NY, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Case Western Reserve University School of Medicine, Cleveland, OH, 4Genentech, Inc., South San Francisco, CA

    Background/Purpose: Although methotrexate (MTX) is often administered in combination with biologics for the treatment of rheumatoid arthritis (RA), it may be discontinued due to intolerance…
  • 1
  • 2
  • 3
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology